Updated Dec. 23, 2013 at 10:53 p.m.

Premium Lock Kidney disease drug developer Nephrogenex files for $46M IPO

Published: 2013-12-23 19:04:00
Updated: 2013-12-23 22:53:20

Print this blog post
Nephrogenex's Pyridorin Nephrogenex's Pyridorin Image 1 of 2 · Next Image…

Nephrogenex's IPO proceeds will finance phase III clinical trials on its diabetic neuropathy drug candidate, a treatment that could compete against other compounds being developed by larger pharmas such as AbbVie, Pfizer and Eli Lilly. Read more about Nephrogenex's plans....

Read More
Read More

WRAL Tech Wire any time: Twitter, Facebook

Copyright 2014 WRAL Tech Wire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL Tech Wire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Scroll